Cripto-1 Expression in Patients with Clear Cell Renal Cell Carcinoma is Associated with Poor Disease Outcome

Overview

Journal J Exp Clin Cancer Res

Publisher Biomed Central

Specialty Oncology

Date 2019 Aug 29

PMID 31455359

Citations 16

Authors

Yi-Jun Xue

Song-Ning Chen

Wei-Guang Chen

Geng-Qing Wu

Yun-Feng Liao

Jian-Bin Xu

Hao Tang

Shui-Hua Yang

Shui-Yong He

Yun-Fei Luo

Zhi-Hui Wu

Hai-Wen Huang

Affiliations

Soon will be listed here.

Abstract

Background: Cripto-1 (CR-1) has been reported to be involved in the development of several human cancers. The potential role of CR-1 in clear cell renal cell carcinoma (ccRCC) is still not clear.

Methods: CR-1 expression was evaluated in ccRCC tissues by Real-time quantitative PCR, Western blot and immunohistochemistry. Serum levels of CR-1 were tested by enzyme-linked immunosorbent assay (ELISA). The clinical significance of CR-1 was analyzed. The effects of CR-1 on cell proliferation, migration, invasion and angiogenesis were investigated in ccRCC cell lines in vitro and in vivo, and markers of the epithelial -mesenchymal transition (EMT) were analyzed. The impact of CR-1 on Wnt/β-catenin signaling pathway was also evaluated in vitro and in vivo.

Results: CR-1 expression was elevated in ccRCC tumor tissues and serum samples. CR-1 expression was correlated with aggressive tumor phenotype and poor survival. Ectopic expression of CR-1 significantly promoted cell proliferation, migration, invasion and angiogenesis whereas knockdown of CR-1 inhibited these activities both in vitro and in vivo. Moreover, we found that CR-1 induced EMT and activated Wnt/β-catenin signaling pathway both in vitro and in vivo.

Conclusions: These results suggest that CR-1 is likely to play important roles in ccRCC development and progression, and that CR-1 is a prognostic biomarker and a promising therapeutic target for ccRCC.

Citing Articles

Acetylation- and ubiquitination-regulated SFMBT2 acts as a tumor suppressor in clear cell renal cell carcinoma.

Xie Q, Hu B, Li H Biol Direct. 2024; 19(1):37.

PMID: 38734627 PMC: 11088781. DOI: 10.1186/s13062-024-00480-3.

Deubiquitinating enzyme OTUD4 stabilizes RBM47 to induce ATF3 transcription: a novel mechanism underlying the restrained malignant properties of ccRCC cells.

Li Z, Tian Y, Zong H, Wang X, Li D, Keranmu A Apoptosis. 2024; 29(7-8):1051-1069.

PMID: 38553613 DOI: 10.1007/s10495-024-01953-6.

Extracellular vesicles in renal cell carcinoma: challenges and opportunities coexist.

Lu Y, Zhang M, Zhou J, Liu X, Wang L, Hu X Front Immunol. 2023; 14:1212101.

PMID: 37469514 PMC: 10352798. DOI: 10.3389/fimmu.2023.1212101.

RNF43 is a novel tumor-suppressor and prognostic indicator in clear cell renal cell carcinoma.

Zhu D, Zhang L, Shi X, Gao S, Yue C, Zhang L Oncol Res. 2023; 29(3):159-174.

PMID: 37304674 PMC: 10208019. DOI: 10.32604/or.2022.03458.

Protective role of remote ischemic conditioning in renal transplantation and partial nephrectomy: A systematic review and meta-analysis of randomized controlled trials.

Zhang W, Wu Y, Zeng M, Yang C, Qiu Z, Liu R Front Surg. 2023; 10:1024650.

PMID: 37091267 PMC: 10113469. DOI: 10.3389/fsurg.2023.1024650.

References

Minchiotti G, Parisi S, Liguori G, DAndrea D, Persico M . Role of the EGF-CFC gene cripto in cell differentiation and embryo development. Gene. 2002; 287(1-2):33-7. DOI: 10.1016/s0378-1119(01)00892-7. View

Normanno N, De Luca A, Maiello M, Bianco C, Mancino M, Strizzi L . CRIPTO-1: a novel target for therapeutic intervention in human carcinoma. Int J Oncol. 2004; 25(4):1013-20. View

Bianco C, Strizzi L, Ebert A, Chang C, Rehman A, Normanno N . Role of human cripto-1 in tumor angiogenesis. J Natl Cancer Inst. 2005; 97(2):132-41. DOI: 10.1093/jnci/dji011. View

Bianco C, Strizzi L, Mancino M, Rehman A, Hamada S, Watanabe K . Identification of cripto-1 as a novel serologic marker for breast and colon cancer. Clin Cancer Res. 2006; 12(17):5158-64. DOI: 10.1158/1078-0432.CCR-06-0274. View

Nishida N, Yano H, Nishida T, Kamura T, Kojiro M . Angiogenesis in cancer. Vasc Health Risk Manag. 2007; 2(3):213-9. PMC: 1993983. DOI: 10.2147/vhrm.2006.2.3.213. View

Watanabe K, Bianco C, Strizzi L, Hamada S, Mancino M, Bailly V . Growth factor induction of Cripto-1 shedding by glycosylphosphatidylinositol-phospholipase D and enhancement of endothelial cell migration. J Biol Chem. 2007; 282(43):31643-55. DOI: 10.1074/jbc.M702713200. View

Watanabe K, Hamada S, Bianco C, Mancino M, Nagaoka T, Gonzales M . Requirement of glycosylphosphatidylinositol anchor of Cripto-1 for trans activity as a Nodal co-receptor. J Biol Chem. 2007; 282(49):35772-86. DOI: 10.1074/jbc.M707351200. View

Zhong X, Zhang L, Jia S, Shi T, Niu Z, Du H . Positive association of up-regulated Cripto-1 and down-regulated E-cadherin with tumour progression and poor prognosis in gastric cancer. Histopathology. 2008; 52(5):560-8. DOI: 10.1111/j.1365-2559.2008.02971.x. View

Ellis L, Hicklin D . VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008; 8(8):579-91. DOI: 10.1038/nrc2403. View

10.

Polyak K, Weinberg R . Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009; 9(4):265-73. DOI: 10.1038/nrc2620. View

11.

Rini B, Campbell S, Escudier B . Renal cell carcinoma. Lancet. 2009; 373(9669):1119-32. DOI: 10.1016/S0140-6736(09)60229-4. View

12.

Grothey A, Galanis E . Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol. 2009; 6(9):507-18. DOI: 10.1038/nrclinonc.2009.110. View

13.

Wu Z, Li G, Wu L, Weng D, Li X, Yao K . Cripto-1 overexpression is involved in the tumorigenesis of nasopharyngeal carcinoma. BMC Cancer. 2009; 9:315. PMC: 2751776. DOI: 10.1186/1471-2407-9-315. View

14.

Bianco C, Rangel M, Castro N, Nagaoka T, Rollman K, Gonzales M . Role of Cripto-1 in stem cell maintenance and malignant progression. Am J Pathol. 2010; 177(2):532-40. PMC: 2913337. DOI: 10.2353/ajpath.2010.100102. View

15.

Ljungberg B, Cowan N, Hanbury D, Hora M, Kuczyk M, Merseburger A . EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol. 2010; 58(3):398-406. DOI: 10.1016/j.eururo.2010.06.032. View

16.

Chaffer C, Weinberg R . A perspective on cancer cell metastasis. Science. 2011; 331(6024):1559-64. DOI: 10.1126/science.1203543. View

17.

De Luca A, Lamura L, Strizzi L, Roma C, DAntonio A, Margaryan N . Expression and functional role of CRIPTO-1 in cutaneous melanoma. Br J Cancer. 2011; 105(7):1030-8. PMC: 3185940. DOI: 10.1038/bjc.2011.324. View

18.

Rangel M, Karasawa H, Castro N, Nagaoka T, Salomon D, Bianco C . Role of Cripto-1 during epithelial-to-mesenchymal transition in development and cancer. Am J Pathol. 2012; 180(6):2188-200. PMC: 3378914. DOI: 10.1016/j.ajpath.2012.02.031. View

19.

Xue Y, Xiao R, Long D, Zou X, Wang X, Zhang G . Overexpression of FoxM1 is associated with tumor progression in patients with clear cell renal cell carcinoma. J Transl Med. 2012; 10:200. PMC: 3492118. DOI: 10.1186/1479-5876-10-200. View

20.

Bianco C, Castro N, Baraty C, Rollman K, Held N, Rangel M . Regulation of human Cripto-1 expression by nuclear receptors and DNA promoter methylation in human embryonal and breast cancer cells. J Cell Physiol. 2012; 228(6):1174-88. PMC: 3573215. DOI: 10.1002/jcp.24271. View